I am surprised by the book published on Sofdra ...early Drugs.com very positive reviews ...pricing usd 1 200..
Net Revenue can be higher, not usd500 but usd 700 or 800...This is minor detail now
FDA protection offers 15-20 years on novel drugs and with some formula mix down the road it can be extended ( most drug companies do it) - not a worry at all at this stage
all indicates that the door is opening..
1% penetration- aud 2 per share just on 6 prescriptions per year
Matt said any leading novel drug should get 30% market ..
Even if he 3x wrong..we still can stare at 10% of market penetration
I am surprised by the book published on Sofdra ...early...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $752.8M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 43.5¢ | 41.0¢ | $2.989M | 7.071M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 408524 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |